Spectrum of candidate molecules against Chikungunya virus - an insight into the antiviral screening platforms

Shree Madhu Bhat, Piya Paul Mudgal, N. Sudheesh, Govindakarnavar Arunkumar

Research output: Contribution to journalReview article

Abstract

Introduction: Chikungunya disease has undergone a phenomenal transition in its status from being recognized as a sporadic infection to acquiring a global prominence over the last couple of decades. The causative agent behind the explosive epidemics worldwide is the re-emerging pathogen, Chikungunya virus (CHIKV). Areas covered: The current review discusses all the possible avenues of antiviral research towards combating CHIKV infection. Aspects of antiviral drug discovery such as antiviral targets, candidate molecules screened, and the various criteria to be a potential inhibitor are all discussed at length. Existing antiviral drug screening tools for CHIKV and their applications are thoroughly described. Clinical trial status of agents with therapeutic potential has been updated with special mention of candidate molecules under patent approval. Databases such as PubMed, Google Scholar, ScienceDirect, Google Patent, and Clinical Trial Registry platforms were referred. Expert opinion: The massive outbreaks of Chikungunya viral disease in the recent past and the serious health concerns imposed thereby, have driven the search for effective therapeutics. The greatest challenge being the non-availability of robust, reproducible, cost-effective and biologically accurate assay models. Nevertheless, there is a need to identify good models mimicking the appropriate microenvironment of an infectious setting.

Original languageEnglish
Pages (from-to)243-264
Number of pages22
JournalExpert Review of Anti-Infective Therapy
Volume17
Issue number4
DOIs
Publication statusPublished - 03-04-2019

Fingerprint

Chikungunya virus
Antiviral Agents
Clinical Trials
Preclinical Drug Evaluations
Expert Testimony
Virus Diseases
Drug Discovery
PubMed
Disease Outbreaks
Registries
Databases
Costs and Cost Analysis
Health
Therapeutics
Infection
Research

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

@article{c3c0289217a4479d8c2c1d83a0ba9a72,
title = "Spectrum of candidate molecules against Chikungunya virus - an insight into the antiviral screening platforms",
abstract = "Introduction: Chikungunya disease has undergone a phenomenal transition in its status from being recognized as a sporadic infection to acquiring a global prominence over the last couple of decades. The causative agent behind the explosive epidemics worldwide is the re-emerging pathogen, Chikungunya virus (CHIKV). Areas covered: The current review discusses all the possible avenues of antiviral research towards combating CHIKV infection. Aspects of antiviral drug discovery such as antiviral targets, candidate molecules screened, and the various criteria to be a potential inhibitor are all discussed at length. Existing antiviral drug screening tools for CHIKV and their applications are thoroughly described. Clinical trial status of agents with therapeutic potential has been updated with special mention of candidate molecules under patent approval. Databases such as PubMed, Google Scholar, ScienceDirect, Google Patent, and Clinical Trial Registry platforms were referred. Expert opinion: The massive outbreaks of Chikungunya viral disease in the recent past and the serious health concerns imposed thereby, have driven the search for effective therapeutics. The greatest challenge being the non-availability of robust, reproducible, cost-effective and biologically accurate assay models. Nevertheless, there is a need to identify good models mimicking the appropriate microenvironment of an infectious setting.",
author = "Bhat, {Shree Madhu} and Mudgal, {Piya Paul} and N. Sudheesh and Govindakarnavar Arunkumar",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/14787210.2019.1595591",
language = "English",
volume = "17",
pages = "243--264",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "4",

}

Spectrum of candidate molecules against Chikungunya virus - an insight into the antiviral screening platforms. / Bhat, Shree Madhu; Mudgal, Piya Paul; Sudheesh, N.; Arunkumar, Govindakarnavar.

In: Expert Review of Anti-Infective Therapy, Vol. 17, No. 4, 03.04.2019, p. 243-264.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Spectrum of candidate molecules against Chikungunya virus - an insight into the antiviral screening platforms

AU - Bhat, Shree Madhu

AU - Mudgal, Piya Paul

AU - Sudheesh, N.

AU - Arunkumar, Govindakarnavar

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Introduction: Chikungunya disease has undergone a phenomenal transition in its status from being recognized as a sporadic infection to acquiring a global prominence over the last couple of decades. The causative agent behind the explosive epidemics worldwide is the re-emerging pathogen, Chikungunya virus (CHIKV). Areas covered: The current review discusses all the possible avenues of antiviral research towards combating CHIKV infection. Aspects of antiviral drug discovery such as antiviral targets, candidate molecules screened, and the various criteria to be a potential inhibitor are all discussed at length. Existing antiviral drug screening tools for CHIKV and their applications are thoroughly described. Clinical trial status of agents with therapeutic potential has been updated with special mention of candidate molecules under patent approval. Databases such as PubMed, Google Scholar, ScienceDirect, Google Patent, and Clinical Trial Registry platforms were referred. Expert opinion: The massive outbreaks of Chikungunya viral disease in the recent past and the serious health concerns imposed thereby, have driven the search for effective therapeutics. The greatest challenge being the non-availability of robust, reproducible, cost-effective and biologically accurate assay models. Nevertheless, there is a need to identify good models mimicking the appropriate microenvironment of an infectious setting.

AB - Introduction: Chikungunya disease has undergone a phenomenal transition in its status from being recognized as a sporadic infection to acquiring a global prominence over the last couple of decades. The causative agent behind the explosive epidemics worldwide is the re-emerging pathogen, Chikungunya virus (CHIKV). Areas covered: The current review discusses all the possible avenues of antiviral research towards combating CHIKV infection. Aspects of antiviral drug discovery such as antiviral targets, candidate molecules screened, and the various criteria to be a potential inhibitor are all discussed at length. Existing antiviral drug screening tools for CHIKV and their applications are thoroughly described. Clinical trial status of agents with therapeutic potential has been updated with special mention of candidate molecules under patent approval. Databases such as PubMed, Google Scholar, ScienceDirect, Google Patent, and Clinical Trial Registry platforms were referred. Expert opinion: The massive outbreaks of Chikungunya viral disease in the recent past and the serious health concerns imposed thereby, have driven the search for effective therapeutics. The greatest challenge being the non-availability of robust, reproducible, cost-effective and biologically accurate assay models. Nevertheless, there is a need to identify good models mimicking the appropriate microenvironment of an infectious setting.

UR - http://www.scopus.com/inward/record.url?scp=85064042838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064042838&partnerID=8YFLogxK

U2 - 10.1080/14787210.2019.1595591

DO - 10.1080/14787210.2019.1595591

M3 - Review article

VL - 17

SP - 243

EP - 264

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 4

ER -